edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Onxeo — 2 videos in collection
Onxeo has a proprietary platON platform based on a unique decoy technology in the field of DNA damage repair inhibition. The lead asset, AsiDNA, is in a Phase Ib triple combination trial with chemotherapy in solid tumours and a second Phase Ib/II trial that aims to demonstrate AsiDNA’s potential to abrogate tumour resistance to PARP inhibitors. The second compound, OX401, is in late preclinical development, optimised to target PARP and is capable of activating the STING pathway. In this video, the CEO of Onxeo Judith Greciet provides an update on the company’s activities and upcoming newsflow.
Get access to the very latest content matched to your personal investment style.